Edit Entry

Paul E Holtzheimer, M.D., M.S.

Title(s):
Associate Professor of Psychiatry
Associate Professor of Surgery
Director, Mood Disorders Service
Staff Physician, White River Junction VAMC

Department(s):
Psychiatry
Surgery

Education:
1990-1995 Pacific Lutheran University, Tacoma, WA.
B.S., Biology, summa cum laude.
B.A., Psychology and Philosophy, summa cum laude.
- Honors in Philosophy.
- Honors in the Integrated Studies Program.
1995-1999 Dartmouth Medical School, Hanover, NH.
M.D., with honors.
2005-2008 Emory University, Atlanta, GA.
M.S., Clinical Research.

Programs:
Program in Experimental and Molecular Medicine

Websites:
mood.dartmouth.edu

Contact Information:

Dartmouth-Hitchcock Medical Center
5D
One Medical Center Drive
Lebanon NH 03756

Office: 603-650-4914
Phone: 603-650-0438
Email: Paul.E.Holtzheimer@hitchcock.org

Asst. Email: mood@dartmouth.edu


Professional Interests:

Dr. Holtzheimerís research program at Dartmouth is focused on the neurobiology and treatment of mood disorders, primarily treatment-resistant depression. Current methodologies include functional and structural neuroimaging and focal neuromodulation techniques such as transcranial magnetic stimulation and deep brain stimulation.

Rotations and Thesis Projects:

Rotations are available in the lab. Most projects will be focused on brain imaging research (structural MRI, resting state functional MRI, diffusion imaging, EEG).

Grant Information:

2011-2016 R01 MH091100-A1 (PI: Paul Holtzheimer, MD)

Biography:

Paul Holtzheimer, MD, is Associate Professor of Psychiatry and Surgery and Director of the Mood Disorders Service at Dartmouth Medical School and Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. He is a Diplomate of the American Board of Psychiatry and Neurology. Dr. Holtzheimer attended Pacific Lutheran University where he graduated summa cum laude with a B.S. in Biology and B.A. in Philosophy and Psychology. He then attended Dartmouth Medical School from 1995 to 1999, graduating with honors. He completed his psychiatry residency at the University of Washington School of Medicine in 2003 followed by a clinical research fellowship in transcranial magnetic stimulation from 2003 to 2004. He joined the faculty of the Department

of Psychiatry and Behavioral Sciences at the Emory University School of Medicine in 2004 where he developed further expertise in treatment-resistant mood disorders, brain imaging techniques and brain stimulation therapies (such as transcranial magnetic stimulation [TMS], electroconvulsive therapy [ECT], and deep brain stimulation [DBS]). Dr. Holtzheimer directed the Resident Psychopharmacology Clinic from 2008 to 2011. Dr. Holtzheimerís research program at Dartmouth is focused on the neurobiology and treatment of mood disorders, primarily treatment-resistant depression. Current methodologies include functional and structural neuroimaging and focal neuromodulation techniques such as transcranial magnetic stimulation and deep brain stimulation. Dr. Holtzheimer is faculty in the Neurosciences Division of the Program in Experimental and Molecular Medicine (PEMM). Clinically, Dr. Holtzheimer provides evaluation and consultation for patients with treatment-resistant mood disorders. Dr. Holtzheimer is an author on over 70 publications in psychiatry, neurosurgery and neuroimaging. He has been an investigator on several clinical trials of novel treatments for mood disorders, including transcranial magnetic stimulation and deep brain stimulation, as well as numerous studies investigating the structural and functional neuroanatomy of mood disorders. He is an Associate Member of the American College of Neuropsychopharmacology where he serves on the Liaison Committee and the Membership Task Force; he also serves as a mentor for the Travel Awardee program. He is a member of the Society of Biological Psychiatry where he currently serves on the Program Committee and the Education Task Force, and is mentor for the Mentor/Mentee Program. He is also a member of the American College of Psychiatrists, the International Society for Electroconvulsive Therapy and Neurostimulation and the Society for Neuroscience.

Mentoring Information:

Carey Allmendinger 2014-present


Selected Publications:

 

Hilimire MR, Mayberg HS, Holtzheimer PE, Broadway JM, Parks NA, DeVylder JE, Corballis PM
Effects of subcallosal cingulate deep brain stimulation on negative self-bias in patients with treatment-resistant depression.
Brain Stimul 2015 Mar-Apr; 8(2):185-91
PMID: 25499035

Riblet N, Larson R, Watts BV, Holtzheimer P
Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis.
Gen Hosp Psychiatry 2014 Sep-Oct; 36(5):466-73
PMID: 24950919

Riva-Posse P, Choi KS, Holtzheimer PE, McIntyre CC, Gross RE, Chaturvedi A, Crowell AL, Garlow SJ, Rajendra JK, Mayberg HS
Defining critical white matter pathways mediating successful subcallosal cingulate deep brain stimulation for treatment-resistant depression.
Biol Psychiatry 2014 Dec 15; 76(12):963-9
PMID: 24832866

Moreines JL, McClintock SM, Kelley ME, Holtzheimer PE, Mayberg HS
Neuropsychological function before and after subcallosal cingulate deep brain stimulation in patients with treatment-resistant depression.
Depress Anxiety 2014 Aug; 31(8):690-8
PMID: 24753183

Delaloye S, Holtzheimer PE
Deep brain stimulation in the treatment of depression.
Dialogues Clin Neurosci 2014 Mar; 16(1):83-91
PMID: 24733973

Wajdik C, Claypoole KH, Fawaz W, Holtzheimer PE 3rd, Neumaier J, Dunner DL, Haynor DR, Roy-Byrne P, Avery DH
No change in neuropsychological functioning after receiving repetitive transcranial magnetic stimulation treatment for major depression.
J ECT 2014 Dec; 30(4):320-4
PMID: 24625717

Karsen EF, Watts BV, Holtzheimer PE
Review of the effectiveness of transcranial magnetic stimulation for post-traumatic stress disorder.
Brain Stimul 2014 Mar-Apr; 7(2):151-7
PMID: 24486424

McGrath CL, Kelley ME, Dunlop BW, Holtzheimer PE 3rd, Craighead WE, Mayberg HS
Pretreatment brain states identify likely nonresponse to standard treatments for depression.
Biol Psychiatry 2014 Oct 1; 76(7):527-35
PMID: 24462230

Choi KS, Holtzheimer PE, Franco AR, Kelley ME, Dunlop BW, Hu XP, Mayberg HS
Reconciling variable findings of white matter integrity in major depressive disorder.
Neuropsychopharmacology 2014 May; 39(6):1332-9
PMID: 24352368

McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS
Toward a neuroimaging treatment selection biomarker for major depressive disorder.
JAMA Psychiatry 2013 Aug; 70(8):821-9
PMID: 23760393